Psoriasis and psoriatic arthritis

Immunological aspects and therapeutic guidelines

C. E M Griffiths, L. Iaccarino, L. Naldi, I. Olivieri, N. Pipitone, C. Salvarani, Andrea Doria

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Psoriasis is an inflammatory skin disease that affects 1-3% of the European population. Chronic plaque psoriasis, the commonest form of the condition - affecting the majority of patients - usually manifests as red, heavily scaled plaques on elbows, knees, scalp and lower back, but any skin surface may be affected. Psoriasis is associated with an inflammatory sero-negative arthritis, namely "psoriatic arthritis", in approximately 15% of patients with psoriasis and occurs more commonly in people with inflammatory bowel disease such as patients with Crohn's disease. Several studies have demonstrated the role of genetic predisposition, innate and adaptive immunity in the pathogenesis of psoriasis. There is considerable evidence that innate immunity and specifically a dysregulation of the innate immune response is central to the development of psoriasis. The role of TNF-α is particularly intriguing. The evidence includes further observations that a variety of anti-TNF approaches such as monoclonal antibodies and fusion proteins of soluble TNF receptors are effective therapies both in psoriasis and psoriatic arthritis. In this review, in addition to pathogenetic aspects, some preliminary guidelines for the use of anti-TNFα therapy in patients with psoriasis and psoriatic arthritis will be discussed.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume24
Issue numberSUPPL. 40
Publication statusPublished - Jan 2006

Fingerprint

Psoriatic Arthritis
Psoriasis
Guidelines
Innate Immunity
Therapeutics
Tumor Necrosis Factor Receptors
Adaptive Immunity
Genetic Predisposition to Disease
Elbow
Scalp
Inflammatory Bowel Diseases
Skin Diseases
Crohn Disease
Arthritis
Knee
Monoclonal Antibodies
Skin

Keywords

  • Anti-TNFα agents
  • IL-2
  • Innate immunity
  • Psoriasis
  • Psoriatic arthritis
  • Spondylo-arthritis
  • TNFα

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Griffiths, C. E. M., Iaccarino, L., Naldi, L., Olivieri, I., Pipitone, N., Salvarani, C., & Doria, A. (2006). Psoriasis and psoriatic arthritis: Immunological aspects and therapeutic guidelines. Clinical and Experimental Rheumatology, 24(SUPPL. 40).

Psoriasis and psoriatic arthritis : Immunological aspects and therapeutic guidelines. / Griffiths, C. E M; Iaccarino, L.; Naldi, L.; Olivieri, I.; Pipitone, N.; Salvarani, C.; Doria, Andrea.

In: Clinical and Experimental Rheumatology, Vol. 24, No. SUPPL. 40, 01.2006.

Research output: Contribution to journalArticle

Griffiths, CEM, Iaccarino, L, Naldi, L, Olivieri, I, Pipitone, N, Salvarani, C & Doria, A 2006, 'Psoriasis and psoriatic arthritis: Immunological aspects and therapeutic guidelines', Clinical and Experimental Rheumatology, vol. 24, no. SUPPL. 40.
Griffiths CEM, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C et al. Psoriasis and psoriatic arthritis: Immunological aspects and therapeutic guidelines. Clinical and Experimental Rheumatology. 2006 Jan;24(SUPPL. 40).
Griffiths, C. E M ; Iaccarino, L. ; Naldi, L. ; Olivieri, I. ; Pipitone, N. ; Salvarani, C. ; Doria, Andrea. / Psoriasis and psoriatic arthritis : Immunological aspects and therapeutic guidelines. In: Clinical and Experimental Rheumatology. 2006 ; Vol. 24, No. SUPPL. 40.
@article{85fa1175140642d0acce667900260544,
title = "Psoriasis and psoriatic arthritis: Immunological aspects and therapeutic guidelines",
abstract = "Psoriasis is an inflammatory skin disease that affects 1-3{\%} of the European population. Chronic plaque psoriasis, the commonest form of the condition - affecting the majority of patients - usually manifests as red, heavily scaled plaques on elbows, knees, scalp and lower back, but any skin surface may be affected. Psoriasis is associated with an inflammatory sero-negative arthritis, namely {"}psoriatic arthritis{"}, in approximately 15{\%} of patients with psoriasis and occurs more commonly in people with inflammatory bowel disease such as patients with Crohn's disease. Several studies have demonstrated the role of genetic predisposition, innate and adaptive immunity in the pathogenesis of psoriasis. There is considerable evidence that innate immunity and specifically a dysregulation of the innate immune response is central to the development of psoriasis. The role of TNF-α is particularly intriguing. The evidence includes further observations that a variety of anti-TNF approaches such as monoclonal antibodies and fusion proteins of soluble TNF receptors are effective therapies both in psoriasis and psoriatic arthritis. In this review, in addition to pathogenetic aspects, some preliminary guidelines for the use of anti-TNFα therapy in patients with psoriasis and psoriatic arthritis will be discussed.",
keywords = "Anti-TNFα agents, IL-2, Innate immunity, Psoriasis, Psoriatic arthritis, Spondylo-arthritis, TNFα",
author = "Griffiths, {C. E M} and L. Iaccarino and L. Naldi and I. Olivieri and N. Pipitone and C. Salvarani and Andrea Doria",
year = "2006",
month = "1",
language = "English",
volume = "24",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "SUPPL. 40",

}

TY - JOUR

T1 - Psoriasis and psoriatic arthritis

T2 - Immunological aspects and therapeutic guidelines

AU - Griffiths, C. E M

AU - Iaccarino, L.

AU - Naldi, L.

AU - Olivieri, I.

AU - Pipitone, N.

AU - Salvarani, C.

AU - Doria, Andrea

PY - 2006/1

Y1 - 2006/1

N2 - Psoriasis is an inflammatory skin disease that affects 1-3% of the European population. Chronic plaque psoriasis, the commonest form of the condition - affecting the majority of patients - usually manifests as red, heavily scaled plaques on elbows, knees, scalp and lower back, but any skin surface may be affected. Psoriasis is associated with an inflammatory sero-negative arthritis, namely "psoriatic arthritis", in approximately 15% of patients with psoriasis and occurs more commonly in people with inflammatory bowel disease such as patients with Crohn's disease. Several studies have demonstrated the role of genetic predisposition, innate and adaptive immunity in the pathogenesis of psoriasis. There is considerable evidence that innate immunity and specifically a dysregulation of the innate immune response is central to the development of psoriasis. The role of TNF-α is particularly intriguing. The evidence includes further observations that a variety of anti-TNF approaches such as monoclonal antibodies and fusion proteins of soluble TNF receptors are effective therapies both in psoriasis and psoriatic arthritis. In this review, in addition to pathogenetic aspects, some preliminary guidelines for the use of anti-TNFα therapy in patients with psoriasis and psoriatic arthritis will be discussed.

AB - Psoriasis is an inflammatory skin disease that affects 1-3% of the European population. Chronic plaque psoriasis, the commonest form of the condition - affecting the majority of patients - usually manifests as red, heavily scaled plaques on elbows, knees, scalp and lower back, but any skin surface may be affected. Psoriasis is associated with an inflammatory sero-negative arthritis, namely "psoriatic arthritis", in approximately 15% of patients with psoriasis and occurs more commonly in people with inflammatory bowel disease such as patients with Crohn's disease. Several studies have demonstrated the role of genetic predisposition, innate and adaptive immunity in the pathogenesis of psoriasis. There is considerable evidence that innate immunity and specifically a dysregulation of the innate immune response is central to the development of psoriasis. The role of TNF-α is particularly intriguing. The evidence includes further observations that a variety of anti-TNF approaches such as monoclonal antibodies and fusion proteins of soluble TNF receptors are effective therapies both in psoriasis and psoriatic arthritis. In this review, in addition to pathogenetic aspects, some preliminary guidelines for the use of anti-TNFα therapy in patients with psoriasis and psoriatic arthritis will be discussed.

KW - Anti-TNFα agents

KW - IL-2

KW - Innate immunity

KW - Psoriasis

KW - Psoriatic arthritis

KW - Spondylo-arthritis

KW - TNFα

UR - http://www.scopus.com/inward/record.url?scp=33645034213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645034213&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - SUPPL. 40

ER -